Lilly(Eli) & Company
NYSE: LLY
$921.49
+$6.45 (+0.7%)
Closing Price on September 20, 2024
LLY Articles
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This...
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
Monday's top analyst upgrades, downgrades and initiations include Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle and Salesforce.com.
Published:
Last Updated:
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
Published:
Eli Lilly reported mixed third-quarter financial results on Thursday before the markets opened.
Published:
Last Updated:
Eli Lilly is scheduled to report its third-quarter earnings before the markets open on Thursday.
Published:
While there were many winners, last week brought a lot of truly bad news or bad reactions for some of the large cap stocks in the market.
Published:
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Published:
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
Published:
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
Published:
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to put the third...
Published:
After the worst quarter in the stock market in four years, a new research report from Merrill Lynch includes the firm's top 10 U.S. ideas for the fourth quarter.
Published:
The market volatility has left all investors a touch shaken, but the chatter of a bear market and a collapse ring pretty hollow when the economy is not in recession.
Published:
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
Published: